Status:

ACTIVE_NOT_RECRUITING

Training Induced Muscle Exosome Release

Lead Sponsor:

Yuan Wen

Collaborating Sponsors:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions:

Metabolism

Eligibility:

All Genders

18-30 years

Phase:

NA

Brief Summary

The primary objective of this study is to quantify miR-1 release from muscle in extra-cellular vesicles following an acute resistance exercise bout and potential delivery to subcutaneous adipose tissu...

Detailed Description

Numerous studies in humans and animals have shown that aerobic exercise is beneficial to adipose tissue function and whole-body metabolism. Both acute and chronic aerobic exercise enhance adipocyte ca...

Eligibility Criteria

Inclusion

  • 18-30 years of age.
  • Either BMI \<25 or \>30.
  • Relatively sedentary, reporting no participation in regular (\>1 day per week) exercise for at least the past 3 months.
  • Non-smoker.

Exclusion

  • BMI between 25 and 30.
  • Evidence or signs and symptoms for cardiovascular disease (previous heart attack, arrhythmias, angina, shortness of breath, extreme fatigue, unusual pain in neck, jaw, throat, upper abdomen, or back, swelling in feet, legs, or ankles).
  • Evidence or signs and symptoms of metabolic syndrome or disorder (diagnosis of diabetes or insulin resistance, elevated BP, high fasting blood sugar, abnormal cholesterol or triglyceride levels).
  • Chronic aspirin or NSAID use (unless it can be safely stopped prior to the biopsies), and any other use of an anticoagulant (e.g., Coumadin) or history of bleeding including history of hypo- or hyper-coagulation disorders.
  • Neurological, musculoskeletal, or other disorder that would preclude safe participation in the weight lifting tasks and all performance tests.
  • Any other medical condition that would interfere with testing or increase one's risk of complications during exercise, as judged by the study physician.
  • Any other condition or events considered exclusionary by the PI and/or physician, such as non-compliance.
  • Lidocaine allergy (1% lidocaine is the local anesthetic used during the muscle biopsy procedure).
  • Pregnancy.

Key Trial Info

Start Date :

March 14 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 30 2026

Estimated Enrollment :

38 Patients enrolled

Trial Details

Trial ID

NCT04500769

Start Date

March 14 2019

End Date

November 30 2026

Last Update

December 10 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Kentucky

Lexington, Kentucky, United States, 40536